Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | PER2 | O15055 | 1/20 | 0.33 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | FABP6 | P51161 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15190271 | 0.92 | SLC6A9 (0.37) | NAAASLC6A9HSD11B1ALDH1A1POLB | |
| Formic Acid SCHEMBL3897768 | 0.86 | PER2 (0.35) | NAAASLC6A9HSD11B1ALDH1A1OPRM1 | |
| SCHEMBL5181671 | 0.86 | DRD2 (0.43) | NAAASLC6A9HSD11B1ALDH1A1HSD17B10 | |
| SCHEMBL3902829 | 0.86 | HSD17B10 (0.44) | NAAASLC6A9HSD11B1ALDH1A1HSD17B10 | |
| SCHEMBL3908041 | 0.85 | PARP1 (0.33) | HSD11B1HSD17B10KCNH2 | |
| Hydrochloric Acid SCHEMBL3896987 | 0.85 | DRD2 (0.42) | NAAAHSD11B1ALDH1A1HSD17B10SIGMAR1 | |
| SCHEMBL3900550 | 0.84 | USP2 (0.38) | NAAASLC6A9HSD11B1ALDH1A1HSD17B10 | |
| SCHEMBL3897560 | 0.81 | ADRB1 (0.37) | HSD11B1ALDH1A1HSD17B10OPRM1 | |
| SCHEMBL5171429 | 0.80 | NAAA (0.41) | NAAAHSD11B1ALDH1A1POLBLMNA | |
| SCHEMBL3860581 | 0.78 | ALDH1A1 (0.43) | SLC6A9ALDH1A1POLBHSD17B10OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773823-B1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-08-21 | — | — | EP | disclosed |
| US-7521449-B2 | 4-arylmorpholin-3-one derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2009-04-21 | — | — | US | disclosed |
| US-20070142349-A1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142349-A1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | ADRB3, ADRA2C, OPRK1 | NAAA 3970/4885SLC6A9 3743/4885HSD11B1 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.